1. Singapore Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharmesis International Ltd.

Pharmesis International Ltd.

SSGX:BFK
0.10
SGD
0.00
(0.00%)
7.26MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.23
3.04
3.01
2.99
3.03
2.8
1.62
2.05
2.29
2.19
1.73
2.26
1.38
- -
Basic EPS, GAAP
0.02
-0.19
0.12
-0.2
-0.11
0.06
-0.77
-0.25
0.05
-0.15
-0.19
0.28
-0.14
- -
Free Cash Flow per Basic Share
0.06
0.41
0.44
-1.4
-0.03
-0.04
-0.18
0.03
-0.04
0.28
-0.46
-0.12
0.07
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.56
4.37
4.18
3.98
3.87
3.92
2.7
2.45
2.5
2.34
1.85
1.94
1.75
2.54
Tangible Book Value per Share
4.11
4.15
4
3.79
3.47
3.54
2.64
2.39
2.44
2.29
1.8
1.9
1.71
2.48
Basic Weighted Avg Shares
20
20
21
23
23
23
23
23
23
23
26
30
32
23
Sales/Revenue/Turnover
65
61
62
69
70
64
37
47
53
50
46
68
44
- -
Operating Margin (%)
1.33
-5.92
5.33
-4.76
-1.27
2.79
-29.11
-9.17
2.01
-4.5
-5.77
3.16
-11.95
- -
Depreciation Expense
4
3
2
2
2
2
2
2
2
2
2
2
3
- -
Net Income, GAAP
- -
-4
2
-5
-2
1
-18
-6
1
-4
-5
8
-4
- -
Effective Tax Rate (%)
- -
- -
0.22
- -
- -
17.23
- -
- -
7.04
- -
- -
9.8
- -
- -
Profit Margin (%)
0.73
-6.25
3.92
-6.74
-3.55
2
-47.5
-12.37
2.22
-7.07
-10.86
12.24
-9.83
- -
Working Capital
72
74
84
81
48
50
10
5
6
5
3
3
-2
7
LT Debt
- -
- -
- -
- -
- -
- -
1
1
2
1
1
1
- -
1
Total Equity
96
91
101
96
94
99
64
58
60
57
54
62
56
60
Return on Invested Capital (%)
0.9
- -
2.77
- -
- -
1.33
- -
- -
1.3
- -
- -
11.17
- -
- -
Return on Capital (%)
-0.01
- -
2.49
- -
- -
-1.58
- -
- -
1.77
- -
- -
12.89
- -
- -
Return on Common Equity (%)
0.52
-4.26
2.67
-4.95
-2.75
1.44
-23.19
-9.84
2.06
-6.39
-9.45
14.7
-7.34
- -

Capital Structure

CNY

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
ST Debt
15
15
15
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
- -
26
37

Working Capital

CNY

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
Total Current Assets
48
39
36
Cash, Cash Equivalents & STI
15
15
13
Accounts Receivable, Net
14
11
12
Inventories
7
7
8
Total Current Liabilities
24
29
30
Payables & Accruals
- -
- -
- -
ST Debt
15
15
15
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.9%
-0.59%
-9.79%
Free Cash Flow
-180.34%
-306.45%
-166.66%
Net Income, GAAP
-293.01%
-180.8%
-151.96%
Sales/Revenue/Turnover
-0.07%
2.2%
-35.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
68
2025
- -
- -
44
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.28
2025
- -
- -
-0.14
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xue Dan Wu
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Singapore Singapore
IPO Date
Oct 6, 2004
Website
pharmesis.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharmesis International Ltd. is an investment holding company primarily engaged in the research, development, manufacture, and distribution of pharmaceutical formulations, Traditional Chinese Medicine (TCM), and health supplements. Founded in 2003 and headquartered in Singapore, the company conducts its primary operations in the People's Republic of China, operating manufacturing and distribution facilities principally through its key operating subsidiaries, including Chengdu Kinna Pharmaceutical Co., Ltd. Pharmesis International operates through distinct business segments: Western Pharmaceuticals, which encompasses the research, production, and marketing of chemical drugs, including anti-inflammatory, respiratory, gastrointestinal, and cardiovascular therapeutic medications; Traditional Chinese Medicine, which focuses on the formulation and manufacture of proprietary herbal medicines, botanical health products, extracts, tablets, granules, and capsules; Distribution and Agency Services, which manages the wholesale distribution, supply chain management, and retail delivery of third-party pharmaceuticals, over-the-counter medicines, and healthcare consumables across hospitals, medical clinics, and pharmacy networks; and Contract Manufacturing Services, providing original equipment manufacturing (OEM) and custom pharmaceutical formulation services in compliance with Good Manufacturing Practice (GMP) quality standards. In recent developments, the company has undertaken strategic operational and commercial adjustments to navigate China's National Centralized Volume-Based Procurement (VBP) policy, shifting its commercial focus toward expanding its proprietary over-the-counter (OTC) healthcare lines, wellness formulations, and dietary health supplements. Additionally, the group has modernized its GMP-certified production infrastructure in Sichuan Province to enhance operating efficiencies, optimized its direct distribution networks through strengthened regional distributor alliances, and introduced new health product formulations tailored to consumer wellness and preventive healthcare demand.